Back to results
US 2020/0049713 A1Published application
Methods of using giant cell nucleic acid characterization in cancer screening, diagnostics, treatment and recurrence
AssigneeCreatv MicroTech, Inc.
InventorsDaniel ADAMS, Cha-Mei TANG
Life of this patent
Estimating the term…
Abstract
The characterization of nucleic acids obtained from cancer-associated cells circulating in the blood of a subject, and the use of such characterizations in cancer screening, diagnostics, treatment, and recurrence, are disclosed.
Claims31
A method of assaying for cancer-associated molecular changes in giant cells, or giant naked nuclei, or both, said method comprising:
- isolating giant cells, or giant naked nuclei, or both, from a biological sample of a subject, and
- analyzing the giant cells and/or giant naked nuclei for cancer-associated molecular changes, thereby analyzing cancer-associated molecular changes in giant cells, or giant naked nuclei, or both.
A method of assaying for cancer-associated molecular changes in giant cells, or giant naked nuclei, or both, said method comprising:
- subjecting a biological sample obtained from a subject to a size exclusion methodology, wherein cells and naked nuclei measuring 8 microns or larger are collected, wherein the collected cells and naked nuclei include giant cells, or giant naked nuclei, or both, and
- analyzing the collected cells and/or naked nuclei for cancer-associated molecular changes, thereby analyzing cancer-associated molecular changes in giant cells, or giant naked nuclei, or both.
A method for determining resistance to a cancer treatment, said method comprising:
- isolating giant cells, or giant naked nuclei, or both, from a biological sample of a subject,
- analyzing the giant cells and/or giant naked nuclei to obtain a second set of cancer-associated molecular changes,
- comparing the second set of cancer-associated molecular changes to a first set of cancer-associated molecular changes obtained from giant cells and/or giant naked nuclei in a similar biological sample obtained from the subject earlier in time,
- wherein when the identity of the first and second sets of cancer-associated molecular changes are different, the subject is determined to be resistant to the cancer treatment.
1 more element
Dependencies are inferred from the claim text.